Boardroom Alpha
S-1 primary document
CLRB · Registration Statement (Form S-1) · Filed May 19, 2026

Cellectar Biosciences IncS-1 exhibit

tm2614975d1_ex5-1.htm

 

Exhibit 5.1

  

 

 

Sidley Austin LLP
2850 Quarry Lake Drive, Suite 301
Baltimore, MD 21209
+1 410 559 2880
+1 202 736 8711 Fax
 
AMERICA · ASIA PACIFIC · EUROPE

 

 

May 19, 2026

 

Cellectar Biosciences, Inc.
100 Campus Drive
Florham Park, New Jersey 07932

 

Ladies and Gentlemen:

 

We refer to the Registration Statement on Form S-1 (the “Registration Statement”) being filed by Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), relating to the registration under the Securities Act of 51,206,051 shares (the “Shares”) of common stock, $0.00001 par value per share (the “Common Stock”), of the Company, consisting of (i) up to 2,116,887 Shares issued in a private placement that closed on May 6, 2026 (the “Private Placement” and such Shares, the “Purchased Shares”), (ii) up to 9,471,086 Shares issuable upon the exercise of Pre-Funded Warrants issued in the Private Placement (the “Pre-Funded Warrants”), (iii) up to 13,206,026 Shares issuable upon the exercise of Series A Warrants issued in the Private Placement (the “Series A Warrants”), (iv) up to 13,206,026 Shares issuable upon the exercise of Series B Warrants issued in the Private Placement (the “Series B Warrants”), and (v) up to 13,206,026 Shares issuable upon the exercise of Series C Warrants issued in the Private Placement (the “Series C Warrants” and, together with the Pre-Funded Warrants, the Series A Warrants and the Series B Warrants, the “Warrants” and the 49,089,164 Shares issuable upon exercise of the Warrants, the “Warrant Shares”). The Shares may be offered and sold by the selling stockholders named in the Registration Statement.

 

This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

 

We have examined the Registration Statement, the Company’s Amended and Restated Certificate of Incorporation, as amended to the date hereof (the “Certificate of Incorporation”), the Company’s Amended and Restated Bylaws, the Warrants and the resolutions adopted by the board of directors of the Company relating to the Registration Statement and the issuance of the Warrants and the Shares by the Company. We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company.

 

Based on the foregoing, and subject to the other qualifications and limitations set forth herein, we are of the opinion that:

 

1.                   the Purchased Shares are validly issued, fully paid and non-assessable.

 

2.                   the Warrant Shares, when duly issued and delivered in accordance with the terms of the Warrants (including the payment of the applicable exercise price), will be validly issued, fully paid and non-assessable.

 

Sidley Austin (DC) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships

 

 

 

Cellectar Biosciences, Inc.

May 19, 2026

Page 2

 

 

In rendering the opinion set forth above, we have assumed that, at the time of the issuance of any Warrant Shares there will be a sufficient number of shares of Common Stock authorized and then available for issuance under the Company’s Certificate of Incorporation as in effect at such time.

 

This opinion letter is limited to the General Corporation Law of the State of Delaware. We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.

 

We hereby consent to the filing of this opinion letter as an Exhibit to the Registration Statement and to all references to our Firm included in or made a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

 

  Very truly yours,
   
   
  /s/ Sidley Austin LLP

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer